There is a high prevalence of CHD (28.0%) among Iranian patients with type 2 diabetes, driven by age, BMI, smoking, and insulin treatment.
No takes yet. Share an insight, caveat, or question.
May inform CHD screening in Iranian T2D patients; cross-sectional data leave causality and generalizability open.
Janghorbani et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: